TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: PK profile of metformin from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK profile of furosemide from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK profile of furosemide from urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Remission of diabetic foot osteomyelitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dabigatran Concentration in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test of Word Reading Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Woodcock-Johnson Psycho-Educational Test Battery-III
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Skin-fold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Willingness-to-pay for patient-centred care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relative abundance of pathobionts and symbionts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in BORDERLINE EVALUATION OF SEVERITY OVER TIME (BEST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Denutrition diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GCF PLAP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCF sclerostin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ileus rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain on the NRS-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of Participants With MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SPECT brain imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Verification of Hematology CBC/Diff parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Eating Disorder Examination Questionnaire (EDE-Q) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective outcome of the TVT operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained social withdrawal
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Anti-HPV16 and anti-HPV18 seroprevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of HSV DNA PCR positive days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Forced Expiratory Volume in One Second (FEV1) AUC0-24h Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion achieving loss of greater than 50% of excess weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of self-reported fall events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of device-reported fall events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Percent Change in Duodenal Polyp Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Grade 2/3 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI with GD enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: MSFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of negative invasive angiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants on Invasive Mechanical Ventilation or Died Prior to or on Day 28
Endpoint domain: Mortality/survival
Primary endpoint: postoperative nausea and vomiting (PONV)
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary coproporphyrins (I/I+III) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in phosphocreatine (PCr) in cerebral grey matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bilirubin Induced Neurologic Dysfunction II Score (BIND II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Venous thromboembolism events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood glucose results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean central systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Objective Response (CR/PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Severe Pneumonia cases appropriately treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of severe pneumonia cases complied with follow-up advice
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intrahepatic lipid content (IHL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatic ATP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatic PI concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in Neonatal Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in perinatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: NPC clinical severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Torque values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resonance Frequency Analysis-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resonance Frequency Analysis-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resonance Frequency Analysis-III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resonance Frequency Analysis-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resonance Frequency Analysis-V
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA methylation levels in circulated tumor and PBMC DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of Power Seat Function Usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power Wheelchair Usage
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Wheelchair Occupancy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Processing Speed Change From Baseline Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EVO Performance Change From Baseline Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any event of venous thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of orthostatic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional Assessment of Cancer Therapy-Breast (FACT-B)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of TBF-12 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of CGI Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Epstein-Barr virus (EBV)-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Uterine Atony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Plasma 25(OH)D concentrations of lactating women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma 25(OH) vitamin D of infants at 6 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast milk concentration of vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Assessment of Infants for Rickets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life for upper extremity transplant recipients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hand Function assessed by Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life assessed by Lawton Instrumental Activities of Daily Living (ADL/IADL) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Primary healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coding Analyst Quota
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Coding Analyst Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiovascular Fitness (VO2 Peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Paretic Thigh Skeletal Muscle Myosin Heavy Chain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Myosin Heavy Chain Isoform 2a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: %MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of growing and mature follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum E2 (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum P (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endometrial thickness (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Validity of self measurement of limb volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMD size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombus Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change of Heart Rate in Response to TSST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: autonomy (ADL loss)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: nutritional status (weight loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting plasma insulin (FPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of C sordellii or C perfringens carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in Tic Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speech intelligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and magnitude of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: time to first detection of parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: parasites density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Plasma Concentration of Unchanged MP-214, M7 and M6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration of Unchanged MP-214, M7 and M6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-through rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cognitive Function (CogState™) Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total pain experience and physical and social disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catastrophizing and perceptions of control
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in skin pain detection threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: kappa value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient-Reported Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Probability of malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Metal ion concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma interleukin-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma c-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma acylcarnitine profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: occurrence of late relapse of persistent atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in disability (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to spontaneous void after catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease
Endpoint domain: Adverse events/effects
Primary endpoint: IPSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caloric intake (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction of the switch
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incremental behavior change for smoking
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Change in trough plasma concentration (Cmin,ss) for non-nucleoside reverse transcriptase inhibitor (NNRTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in area under plasma concentration-time curve over dosing interval (AUC0-τ) for nucleoside reverse transcriptase inhibitor (NRTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in area under plasma concentration-time curve from 0 to 12 hours for didanosine (ddI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Spironolactone and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Spironolactone and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of Spironolactone and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 1-dehydrothromboxane B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Omega-3 Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 8-hydroxy-2' -deoxyguanosine (8- OHdG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 8-isoprostane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: number of participants having advanced neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients exposed to allogenic blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability (side effects)
Endpoint domain: Adverse events/effects
Primary endpoint: Physician attitude about the utility of contrast-enhanced cone beam CT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blinded Match between contrast and non-contrast enhanced CBCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Skin Conductance Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Heart Rate (Beats Per Minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Corrugator Muscle (EMG) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Full-field scotopic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax and AUC of study drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flortaucipir Qualitative Results (Visual Reads)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flortaucipir Quantitative Results (SUVr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETP of various heart chambers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak height of various heart chambers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lag time of various heart chambers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to peak of various heart chambers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plaque Index Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding on probing score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recession width change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of young adults hospitalized with primary diagnosis of Acute Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Skin Irritation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Atrial fibrillation termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Days in ADT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean of Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Perceived Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Myocardial transverse relaxation time (T2) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distance from anterior abdominal wall to intraperitoneal visceral structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Neutrophil Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to Platelet Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plerixafor-associated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Score change of 100 mm VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vibration frequency ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Get up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of H2S
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synthase nucleic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary vascular remodeling indexes on HRCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean log transformed IL-10:IL-12p70 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal Exercise Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Tested Positive for Anti-denosumab Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of Trypanosoma cruzi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Analgesic needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes